In vitro susceptibility testing of Dientamoeba fragilis

Nagata, N; Marriott, D; Harkness, J; Ellis, JT; Stark, D

In vitro susceptibility testing of Dientamoeba fragilis

Nagata, N Marriott, D Harkness, J Ellis, JT

Stark, D

Permalink

Publication Type:: Journal Article
Citation:: Antimicrobial Agents and Chemotherapy, 2012, 56 (1), pp. 487 - 494
Issue Date:: 2012-01-01

Closed Access

	Filename	Description	Size
	2010003698OK.pdf		350.34 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Nagata, N	en_US
dc.contributor.author	Marriott, D	en_US
dc.contributor.author	Harkness, J	en_US
dc.contributor.author	Ellis, JT https://orcid.org/0000-0001-7328-4831	en_US
dc.contributor.author	Stark, D	en_US
dc.date.issued	2012-01-01	en_US
dc.identifier.citation	Antimicrobial Agents and Chemotherapy, 2012, 56 (1), pp. 487 - 494	en_US
dc.identifier.issn	0066-4804	en_US
dc.identifier.uri	http://hdl.handle.net/10453/18510
dc.description.abstract	Dientamoeba fragilis is a commonly encountered trichomonad which has been implicated as a cause of gastrointestinal disease in humans. Despite the frequency of reports recording infections with this parasite, little research has been undertaken in terms of antimicrobial susceptibility. The aim of this study was to evaluate the susceptibility of D. fragilis to several commonly used antiparasitic agents: diloxanide furoate, furazolidone, iodoquinol, metronidazole, nitazoxanide, ornidazole, paromomycin, secnidazole, ronidazole, tetracycline, and tinidazole. Antibiotic susceptibility testing was performed on four clinical strains of D. fragilis, designated A, E, M, and V, respectively. Molecular testing followed, and all strains were determined to be genotype 1. The activities of antiprotozoal compounds at concentrations ranging from 2 μg/ml to 500 μg/ml were determined via cell counts of D. fragilis trophozoites grown in dixenic culture. Minimum lethal concentrations (MLCs) were as follows: ornidazole, 8 to 16 μg/ml; ronidazole, 8 to 16 μg/ml; tinidazole, 31 μg/ml; metronidazole, 31 μg/ml; secnidazole, 31 to 63 μg/ml; nitazoxanide, 63 μg/ml; tetracycline, 250 μg/ml; furazolidone, 250 to 500 μg/ml; iodoquinol, 500 μg/ml; paromomycin, 500 μg/ml; and diloxanide furoate, >500 μg/ml. This is the first study to report the profiles of susceptibility to a wide range of commonly used treatments for clinical isolates of D. fragilis. Our study indicated 5-nitroimidazole derivatives to be the most active compounds in vitro against D. fragilis. Copyright © 2012, American Society for Microbiology. All Rights Reserved.	en_US
dc.relation.ispartof	Antimicrobial Agents and Chemotherapy	en_US
dc.relation.isbasedon	10.1128/AAC.05125-11	en_US
dc.subject.classification	Microbiology	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Dientamoeba	en_US
dc.subject.mesh	Gram-Negative Bacteria	en_US
dc.subject.mesh	Gram-Positive Bacteria	en_US
dc.subject.mesh	Dientamoebiasis	en_US
dc.subject.mesh	Nitroimidazoles	en_US
dc.subject.mesh	Antiprotozoal Agents	en_US
dc.subject.mesh	Cell Culture Techniques	en_US
dc.subject.mesh	Cell Count	en_US
dc.subject.mesh	Bacterial Typing Techniques	en_US
dc.subject.mesh	Microbial Sensitivity Tests	en_US
dc.subject.mesh	Dose-Response Relationship, Drug	en_US
dc.subject.mesh	Genotype	en_US
dc.subject.mesh	Trophozoites	en_US
dc.title	In vitro susceptibility testing of Dientamoeba fragilis	en_US
dc.type	Journal Article
utslib.citation.volume	1	en_US
utslib.citation.volume	56	en_US
utslib.for	110803 Medical Parasitology	en_US
utslib.for	0605 Microbiology	en_US
utslib.for	1108 Medical Microbiology	en_US
utslib.for	1115 Pharmacology and Pharmaceutical Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	closed_access
pubs.issue	1	en_US
pubs.publication-status	Published	en_US
pubs.volume	56	en_US

Abstract:

Dientamoeba fragilis is a commonly encountered trichomonad which has been implicated as a cause of gastrointestinal disease in humans. Despite the frequency of reports recording infections with this parasite, little research has been undertaken in terms of antimicrobial susceptibility. The aim of this study was to evaluate the susceptibility of D. fragilis to several commonly used antiparasitic agents: diloxanide furoate, furazolidone, iodoquinol, metronidazole, nitazoxanide, ornidazole, paromomycin, secnidazole, ronidazole, tetracycline, and tinidazole. Antibiotic susceptibility testing was performed on four clinical strains of D. fragilis, designated A, E, M, and V, respectively. Molecular testing followed, and all strains were determined to be genotype 1. The activities of antiprotozoal compounds at concentrations ranging from 2 μg/ml to 500 μg/ml were determined via cell counts of D. fragilis trophozoites grown in dixenic culture. Minimum lethal concentrations (MLCs) were as follows: ornidazole, 8 to 16 μg/ml; ronidazole, 8 to 16 μg/ml; tinidazole, 31 μg/ml; metronidazole, 31 μg/ml; secnidazole, 31 to 63 μg/ml; nitazoxanide, 63 μg/ml; tetracycline, 250 μg/ml; furazolidone, 250 to 500 μg/ml; iodoquinol, 500 μg/ml; paromomycin, 500 μg/ml; and diloxanide furoate, >500 μg/ml. This is the first study to report the profiles of susceptibility to a wide range of commonly used treatments for clinical isolates of D. fragilis. Our study indicated 5-nitroimidazole derivatives to be the most active compounds in vitro against D. fragilis. Copyright © 2012, American Society for Microbiology. All Rights Reserved.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/18510